(Reuters) -Cartesian Therapeutics said on Tuesday that its experimental immune disorder therapy met the main goal in a mid-stage trial.
The therapy known as descartes-08 is a chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, to treat patients with myasthenia gravis an autoimmune disorder that causes disabling muscle weakness and fatigue.
The company said 71% of patients in the study showed significant improvement in symptoms as measured on a disease severity scale at three months, compared to 25% of patients who were given a placebo.
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)
